Hybrid & Decentralized Trials

Hybrid and decentralized approaches have the potential to revolutionize clinical trials. These new technologies have existed for years, but the COVID-19 pandemic in 2020 hastened their adoption by drug developers.

Sponsor companies now have the ability to take tasks that used to be performed in clinics and take them into the homes of patients. By making trials more patient-friendly, drug developers should be able to recruit and retain more patients and increase patient diversity in studies.

In this e-book, we look at the adoption of decentralized trials, the challenges companies face, and the promise they hold to reduce the time and cost of conducting trials.